Atrial Septal Defect Closure in Geriatric Patients

Immediate and Short-Term Outcome of Percutaneous Atrial Septal Defects Closure in Adult Patients

“…Supporting the finding of our study, various past studies have reported a significant improvement in the functional class of the adult (≥40 years) patients after percutaneous atrial septal defects (ASD) closure in adult patients [3,[6][7][12][13]. It is also reported that ASD device closure leads to favorable and positive cardiac remodeling [6][7]12] and showed systematic regression and improvement of RV enlargement, SPAP, and RV and LV function [3,7,[13][14].…”

“…In our study, all the patients were free of any post-procedure in-hospital major complications, similarly, either low or no complications were reported by various studies from different parts of the world [3,[6][7][12][13]15]. In our study, mean PAP decreased to <50 mmHg in 96.6% of the patients, and functional class improved in 90% of the patients, which is higher than the 74% reported by Akagi et al [7].…”

“…ASD is one of the common congenital heart diseases in the adult population and if left untreated, can cause right-sided heart failure, left ventricular failure, atrial fibrillation or flutter, and irreversible severe pulmonary artery hypertension [3,[6][7]11]. This study was conducted to evaluate the immediate and shortterm outcomes of percutaneous atrial septal defects closure in adult patients.…”

“…Patients with ASD II remain asymptomatic until late, when they present in adult life with palpitation, decreased exercise tolerance, and arrhythmia [3][4][5][6]. Therefore, the closure of ASD with a significant left to right shunt results in improved functional capacity and improves arrhythmias, which becomes more responsive to treatment [3,5,7]. However ASD closure in adult patients has certain risks, specifically may result in pulmonary edema and heart failure and may lead to death.…”

Outcomes of Device Closure of Atrial Septal Defects

“…Masura and associates concluded that ASO occlusion of ASDs is associated with safety and effectiveness in producing full occlusion of secundum ASDs up to a diameter of 21 mm [ 61 ]. Subsequently other investigations in children [ 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ] and adults [ 61 , 64 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 ] including FDA-approved US trial [ 80 ] and multi-institutional European studies [ 70 , 81 ], as reviewed and tabulated elsewhere [ 20 , 21 , 24 , 82 ], demonstrated excellent results. These studies confirmed encouraging results with full occlusion rates of 62 to 96% at device implantation, which increased further at 6- to 12-month follow-up evaluation to 83 to 99% [ 59 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , …”